Wedge Capital Management L L P NC lowered its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.9% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 1,382,080 shares of the medical equipment provider’s stock after selling 41,999 shares during the period. Zimmer Biomet Holdings comprises 1.7% of Wedge Capital Management L L P NC’s holdings, making the stock its 4th largest position. Wedge Capital Management L L P NC’s holdings in Zimmer Biomet Holdings were worth $177,459,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Parkside Financial Bank & Trust boosted its position in shares of Zimmer Biomet Holdings by 2.7% in the first quarter. Parkside Financial Bank & Trust now owns 839 shares of the medical equipment provider’s stock valued at $102,000 after buying an additional 22 shares during the last quarter. Parallel Advisors LLC boosted its position in shares of Zimmer Biomet Holdings by 20.8% in the first quarter. Parallel Advisors LLC now owns 1,157 shares of the medical equipment provider’s stock valued at $138,000 after buying an additional 199 shares during the last quarter. IHT Wealth Management LLC boosted its position in shares of Zimmer Biomet Holdings by 28.4% in the first quarter. IHT Wealth Management LLC now owns 1,158 shares of the medical equipment provider’s stock valued at $139,000 after buying an additional 256 shares during the last quarter. Sandy Spring Bank boosted its position in shares of Zimmer Biomet Holdings by 1.7% in the first quarter. Sandy Spring Bank now owns 1,222 shares of the medical equipment provider’s stock valued at $149,000 after buying an additional 20 shares during the last quarter. Finally, Ledyard National Bank boosted its position in shares of Zimmer Biomet Holdings by 9.3% in the first quarter. Ledyard National Bank now owns 1,293 shares of the medical equipment provider’s stock valued at $157,000 after buying an additional 110 shares during the last quarter. 83.62% of the stock is currently owned by institutional investors.

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) opened at 110.13 on Friday. The stock has a market capitalization of $22.27 billion, a price-to-earnings ratio of 31.37 and a beta of 1.20. Zimmer Biomet Holdings, Inc. has a 52 week low of $95.63 and a 52 week high of $133.49. The firm’s 50-day moving average is $125.44 and its 200-day moving average is $121.28.

Zimmer Biomet Holdings (NYSE:ZBH) last issued its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 earnings per share for the quarter, missing the Zacks’ consensus estimate of $2.10 by $0.02. Zimmer Biomet Holdings had a net margin of 9.12% and a return on equity of 16.70%. The firm had revenue of $1.95 billion during the quarter, compared to the consensus estimate of $1.95 billion. During the same quarter last year, the firm posted $2.02 earnings per share. Zimmer Biomet Holdings’s revenue was up 1.1% compared to the same quarter last year. On average, equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post $8.24 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Friday, September 22nd will be issued a $0.24 dividend. The ex-dividend date is Thursday, September 21st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.87%. Zimmer Biomet Holdings’s dividend payout ratio (DPR) is 27.59%.

TRADEMARK VIOLATION WARNING: This piece of content was originally posted by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.watchlistnews.com/wedge-capital-management-l-l-p-nc-decreases-stake-in-zimmer-biomet-holdings-inc-nysezbh/1474516.html.

Several brokerages have recently weighed in on ZBH. Stifel Nicolaus reissued a “hold” rating and set a $125.00 price target on shares of Zimmer Biomet Holdings in a research report on Friday, July 14th. Needham & Company LLC boosted their price target on shares of Zimmer Biomet Holdings from $151.00 to $153.00 and gave the company a “strong-buy” rating in a research report on Friday, April 28th. Oppenheimer Holdings, Inc. set a $132.00 price target on shares of Zimmer Biomet Holdings and gave the company a “buy” rating in a research report on Friday, April 28th. Zacks Investment Research cut shares of Zimmer Biomet Holdings from a “hold” rating to a “strong sell” rating in a research report on Tuesday. Finally, BMO Capital Markets reissued a “buy” rating and set a $136.00 price target on shares of Zimmer Biomet Holdings in a research report on Tuesday, July 11th. Four equities research analysts have rated the stock with a sell rating, seven have given a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Zimmer Biomet Holdings currently has a consensus rating of “Hold” and an average target price of $137.76.

In other news, insider Sang Yi sold 17,731 shares of the business’s stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $124.56, for a total value of $2,208,573.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Tony W. Collins sold 16,986 shares of the business’s stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $121.74, for a total value of $2,067,875.64. The disclosure for this sale can be found here. 1.07% of the stock is currently owned by insiders.

About Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.